GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells

GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells

Doxorubicin (DOX) is an anticancer drug widely used in oncology, especially for breast cancer. The main limitation of DOX treatment is its cardiotoxicity due to the cumulative dose. Clinically, DOX-induced cardiomyopathy develops as a progressive heart failure caused by a progressive cardiomyocyte’s...

Full description

Bibliographic Details
Main Authors: Matthieu Dallons, Esma Alpan, Corentin Schepkens, Vanessa Tagliatti, Jean-Marie Colet
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cells
Subjects:
doxorubicin
cardiotoxicity
H9C2
GPR91
succinate
<i>cis</i>-epoxysuccinate
Online Access:https://www.mdpi.com/2073-4409/9/10/2177

Similar Items

Similar Items